PFIZER INC. DL-05 FWB:PFE Price, Chart, News & Insight

Pfizer Inc. announced it has reached settlement agreements with generic drugmakers Dexcel Pharma, Hikma Pharmaceuticals, and Cipla regarding patent litigation over its heart disease treatment VYNDAMAX. The agreements extend the drug’s U.S. patent protection to June 2031, delaying expected generic competition.

As a result, Pfizer now anticipates VYNDAMAX revenues to remain relatively stable from 2028 through mid-2031, instead of declining earlier as previously expected. The drug currently holds a strong market position, accounting for around 75% of prescriptions in its category.

The company emphasized that the outcome supports both patient access and the protection of its intellectual property, while ongoing litigation could still impact future developments.

Source: Business Wire

💬 🔗

The Investor 04-28-26

Bristol Myers Squibb and Pfizer announced a collaboration with Mark Cuban Cost Plus Drug Company to offer Eliquis (apixaban) directly to U.S. patients through the online platform, expanding access to the widely prescribed blood thinner.

Starting April 27, 2026, a 30-day supply of Eliquis will be available for $345, providing a lower-cost option for cash-paying patients and increasing pricing transparency. The move builds on earlier direct-to-patient initiatives aimed at improving affordability and access.

The companies said the partnership supports efforts to reduce barriers to essential medications, particularly for patients managing conditions such as atrial fibrillation and blood clots.
Business Wire

💬 🔗

The Investor 04-26-26

Pfizer Inc. (NYSE: PFE) declared a $0.43 second-quarter 2026 dividend on the common stock, payable June 12, 2026, to holders of the Common Stock of record at the close of business on May 8, 2026.

💬 🔗

Global Finance News 04-24-26

Pfizer and Valneva announced positive Phase 3 results for their Lyme disease vaccine candidate, showing efficacy above 70% in preventing the disease in individuals aged five and older.

The investigational vaccine demonstrated strong efficacy of around 73–75% in key analyses and was well tolerated with no major safety concerns, supporting plans for regulatory submissions.

The results mark a significant step toward the first approved human vaccine for Lyme disease, addressing a growing unmet medical need in North America and Europe.

💬 🔗

WS Investor 03-23-26

Pfizer reported positive Phase 3 results showing that the combination of TALZENNA and XTANDI significantly improved radiographic progression-free survival in patients with metastatic hormone-sensitive prostate cancer carrying HRR gene mutations . The study met its primary endpoint with a clinically meaningful reduction in the risk of disease progression or death compared to standard treatment.

The treatment demonstrated consistent benefits across both BRCA and non-BRCA patient groups, while interim data also संकेत a strong trend toward improved overall survival. Additional secondary endpoints, including response rates and time to PSA progression, also showed favorable outcomes.

Pfizer plans to engage with global regulators to potentially expand the indication of TALZENNA to earlier-stage prostate cancer, highlighting the combination’s potential to shift treatment earlier in the disease course and reinforce the company’s precision oncology strategy.
Business Wire

💬 🔗

Global Finance News 03-19-26

Pfizer Reports Positive Phase 2 Results for Next-Generation Breast Cancer Drug

Pfizer announced positive topline Phase 2 results for its investigational CDK4 inhibitor atirmociclib in patients with advanced or metastatic breast cancer.

The FOURLIGHT-1 study met its primary endpoint, showing a 40% reduction in the risk of disease progression or death compared to standard treatments, with a manageable safety profile. The results support further development of atirmociclib as a potential next-generation therapy, with ongoing Phase 3 trials in earlier treatment settings.
Business Wire

💬 🔗

WS Investor 03-17-26

Pfizer reported positive Phase 2 trial results for its investigational trispecific antibody tilrekimig (PF-07275315) in adults with moderate to severe atopic dermatitis, meeting the study’s primary endpoint.

The treatment significantly increased the share of patients achieving a 75% reduction in eczema severity (EASI-75) after 16 weeks compared with placebo, with response rates of 38.7%, 51.9% and 49.4% across tested doses. The drug was generally well tolerated, with adverse event rates similar to placebo.

Tilrekimig targets three inflammatory pathways—IL-4, IL-13 and TSLP—and could become a first-in-class once-monthly therapy for multiple Type-2 inflammatory diseases, including atopic dermatitis, asthma and COPD. Pfizer said it plans to advance the therapy into Phase 3 development later this year.
Source: Business Wire

💬 🔗

WS Investor 03-09-26

Pfizer Inc. and Astellas Pharma Inc. said their Phase 3 EV-304 (KEYNOTE-B15) trial showed that PADCEV (enfortumab vedotin) plus Keytruda (pembrolizumab) significantly improved outcomes in cisplatin-eligible muscle-invasive bladder cancer (MIBC) patients when used before and after surgery.

The combination reduced the risk of recurrence, progression or death by 47% versus standard neoadjuvant gemcitabine and cisplatin (HR 0.53; p<.0001), with 79.4% of patients event-free at two years compared with 66.2% under standard care. Overall survival improved by 35% (HR 0.65; p=.0029), while 55.8% of patients achieved a pathological complete response at surgery, versus 32.5% in the chemotherapy arm.

Results were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco. The companies said the platinum-free regimen could establish a new standard of care if approved. PADCEV plus pembrolizumab is already approved in the U.S. for perioperative treatment in cisplatin-ineligible MIBC patients.

Source: Business Wire

💬 🔗

Global Finance News 02-28-26

Pfizer Reports Positive BREAKWATER Data for BRAFTOVI in Metastatic Colorectal Cancer

Pfizer Inc. announced that Cohort 3 of the Phase 3 BREAKWATER trial showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for BRAFTOVI® (encorafenib) combined with cetuximab (ERBITUX®) and FOLFIRI in previously untreated patients with BRAF V600E–mutant metastatic colorectal cancer (mCRC).

The BRAFTOVI-based regimen improved PFS versus FOLFIRI with or without bevacizumab, with overall survival also showing clinically meaningful prolongation. The safety profile was consistent with known components of the regimen, and no new safety signals were identified.

Earlier results from the same cohort demonstrated positive objective response rate (ORR) data, presented at the 2026 ASCO GI Cancers Symposium. Detailed findings will be submitted to regulators to support potential approval of BRAFTOVI plus cetuximab and FOLFIRI in this first-line setting.

BRAFTOVI is already approved in combination with cetuximab and mFOLFOX6 under accelerated approval for treatment-naïve patients with BRAF V600E–mutant mCRC, based on confirmed response rates.

Colorectal cancer is the third most common cancer globally, and BRAF mutations occur in 8–12% of metastatic cases, typically associated with poor prognosis.

Source: Business Wire

💬 🔗

The Investor 02-17-26

Pfizer Inc. reported solid full-year 2025 results and reaffirmed its full-year 2026 financial guidance, highlighting strong execution and continued progress in its late-stage pipeline.

Pfizer generated full-year 2025 revenues of $62.6 billion, representing a 2% year-over-year operational decline, while revenues excluding COVID-19 products Paxlovid and Comirnaty grew 6% operationally. Reported diluted EPS for the year was $1.36, with adjusted diluted EPS of $3.22. Fourth-quarter 2025 revenues totaled $17.6 billion, down 3% operationally year over year, while adjusted diluted EPS came in at $0.66.

The company reaffirmed its 2026 outlook, maintaining revenue guidance of $59.5–$62.5 billion and adjusted diluted EPS guidance of $2.80–$3.00. Pfizer also emphasized pipeline momentum, with 11 key pivotal studies initiated in 2025 and approximately 20 pivotal study starts planned for 2026.

Source: Pfizer Inc. press release

💬 🔗

WS Investor 02-03-26

FWB:PFEFollow

FWB:PFE